|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FAM207A |
Gene summary for FAM207A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FAM207A | Gene ID | 85395 |
| Gene name | SLX9 ribosome biogenesis factor | |
| Gene Alias | C21orf70 | |
| Cytomap | 21q22.3 | |
| Gene Type | protein-coding | GO ID | GO:0000462 | UniProtAcc | Q9NSI2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 85395 | FAM207A | LZE2T | Human | Esophagus | ESCC | 3.50e-02 | 4.38e-01 | 0.082 |
| 85395 | FAM207A | LZE20T | Human | Esophagus | ESCC | 1.45e-02 | 1.81e-01 | 0.0662 |
| 85395 | FAM207A | LZE22T | Human | Esophagus | ESCC | 3.99e-03 | 3.08e-01 | 0.068 |
| 85395 | FAM207A | LZE24T | Human | Esophagus | ESCC | 8.85e-24 | 5.39e-01 | 0.0596 |
| 85395 | FAM207A | LZE21T | Human | Esophagus | ESCC | 1.35e-06 | 3.16e-01 | 0.0655 |
| 85395 | FAM207A | P1T-E | Human | Esophagus | ESCC | 1.01e-06 | 3.03e-01 | 0.0875 |
| 85395 | FAM207A | P2T-E | Human | Esophagus | ESCC | 4.45e-37 | 6.95e-01 | 0.1177 |
| 85395 | FAM207A | P4T-E | Human | Esophagus | ESCC | 3.42e-48 | 1.10e+00 | 0.1323 |
| 85395 | FAM207A | P5T-E | Human | Esophagus | ESCC | 2.78e-62 | 1.02e+00 | 0.1327 |
| 85395 | FAM207A | P8T-E | Human | Esophagus | ESCC | 6.78e-20 | 3.19e-01 | 0.0889 |
| 85395 | FAM207A | P9T-E | Human | Esophagus | ESCC | 1.06e-20 | 5.70e-01 | 0.1131 |
| 85395 | FAM207A | P10T-E | Human | Esophagus | ESCC | 1.54e-41 | 7.45e-01 | 0.116 |
| 85395 | FAM207A | P11T-E | Human | Esophagus | ESCC | 6.67e-13 | 3.87e-01 | 0.1426 |
| 85395 | FAM207A | P12T-E | Human | Esophagus | ESCC | 3.15e-28 | 5.72e-01 | 0.1122 |
| 85395 | FAM207A | P15T-E | Human | Esophagus | ESCC | 1.09e-22 | 4.72e-01 | 0.1149 |
| 85395 | FAM207A | P16T-E | Human | Esophagus | ESCC | 2.22e-61 | 1.03e+00 | 0.1153 |
| 85395 | FAM207A | P17T-E | Human | Esophagus | ESCC | 5.36e-13 | 5.82e-01 | 0.1278 |
| 85395 | FAM207A | P19T-E | Human | Esophagus | ESCC | 1.10e-03 | 2.55e-01 | 0.1662 |
| 85395 | FAM207A | P20T-E | Human | Esophagus | ESCC | 6.55e-15 | 2.69e-01 | 0.1124 |
| 85395 | FAM207A | P21T-E | Human | Esophagus | ESCC | 2.01e-53 | 9.18e-01 | 0.1617 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FAM207A | SNV | Missense_Mutation | novel | c.586N>T | p.Arg196Trp | p.R196W | Q9NSI2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A3TN-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| FAM207A | SNV | Missense_Mutation | rs764807371 | c.358N>A | p.Glu120Lys | p.E120K | Q9NSI2 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| FAM207A | SNV | Missense_Mutation | rs369865339 | c.334N>T | p.Arg112Cys | p.R112C | Q9NSI2 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FAM207A | SNV | Missense_Mutation | novel | c.587N>A | p.Arg196Gln | p.R196Q | Q9NSI2 | protein_coding | tolerated(0.08) | probably_damaging(0.997) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FAM207A | SNV | Missense_Mutation | c.494N>T | p.Ala165Val | p.A165V | Q9NSI2 | protein_coding | tolerated(0.23) | benign(0.114) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
| FAM207A | SNV | Missense_Mutation | rs764807371 | c.358G>A | p.Glu120Lys | p.E120K | Q9NSI2 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| FAM207A | SNV | Missense_Mutation | novel | c.313N>G | p.Lys105Glu | p.K105E | Q9NSI2 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| FAM207A | SNV | Missense_Mutation | rs764807371 | c.358N>A | p.Glu120Lys | p.E120K | Q9NSI2 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FAM207A | SNV | Missense_Mutation | rs371767467 | c.335G>A | p.Arg112His | p.R112H | Q9NSI2 | protein_coding | tolerated(0.09) | possibly_damaging(0.495) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FAM207A | SNV | Missense_Mutation | novel | c.551N>T | p.Ala184Val | p.A184V | Q9NSI2 | protein_coding | tolerated(0.11) | benign(0.009) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |